Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02134808 · ClinicalTrials.gov registry record · Phase 4
Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
A Phase 4 study, sponsored by Perry Renshaw.
- Completed
- Registry status
- Phase 4
- Development phase
- 71
- Enrollment target
NCT02134808 is a Phase 4 study that has completed, run by Perry Renshaw. The registered enrollment target is 71 participants.
The verdict
NCT02134808, a Phase 4 study, has completed, sponsored by Perry Renshaw.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 71 participants
- Enrollment target
Study Summary
The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for eight weeks will be associated with significant increases in frontal lobe phosphocreatine and beta-nucleoside triphosphate (β-NTP) concentrations. A secondary hypothesis is that decreased depressive symptoms measured with the Children's Depression Rating Scale-Revised (CDRS-R) and Montgomery-Asberg Depression Rating Scale (MADRS) will be reciprocally correlated with increased β-NTP concentrations.
Interventions
- DRUG Placebo
- DRUG Creatine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2014-11-21 |
| Est. Completion | 2017-06-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02134808
The ClinicalTrials.gov registry entry for NCT02134808 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Perry Renshaw, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02134808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02134808 about?
NCT02134808 is a clinical study titled "Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder". The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for eight weeks will be associated with significant increases in frontal lobe phosphocreatine and beta-nucleoside triphosphate (β-NTP) concentrations. A secondary hypothesis is that decreased depressive symptoms me...
What is the current status of trial NCT02134808?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 71 participants. The study started on 2014-11-21. Estimated completion is 2017-06-27.
What interventions are being tested in trial NCT02134808?
The interventions under investigation include: Placebo (DRUG), Creatine (DRUG).
Who is sponsoring clinical trial NCT02134808?
This trial is sponsored by Perry Renshaw, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.